Back to top

Analyst Blog

Durata Therapeutics, Inc. (DRTX - Snapshot Report) continues to progress with its lead candidate, dalbavancin, which is being developed for the treatment of patients with complicated skin and soft tissue infections (cSSTI).

Earlier this month, Durata submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for dalbavancin seeking approval for the marketing and sale of dalbavancin for the treatment of patients with cSSTI.

Durata recently announced that its MAA has been accepted for review by the EMA.  Durata expects a decision by the first half of 2015.

The MAA was submitted based on positive results from three phase III trials – DISCOVER 1, DISCOVER 2 and VER001-9.

The data from DISCOVER 1 and DISCOVER 2 indicated that dalbavancin achieved its primary efficacy endpoint of non-inferiority of clinical response at 48 to 72 hours after initiation of therapy. Dalbavacin also achieved its secondary endpoint, which was clinical success at the end of treatment.

We remind investors that the U.S. Food and Drug Administration (FDA) accepted Durata’s New Drug Application (NDA) for Dalvance (dalbavancin) for priority review in Nov 2013.

Durata is seeking FDA approval of Dalvance for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive microorganisms, including MRSA (methicillin resistant Staphylococcus aureus). A decision by the FDA is expected by May 26, 2014.

Durata currently does not have any marketed product in its portfolio. Hence, the successful development and commercialization of dalbavancin will be a big boost to the company’s portfolio.

Durata currently carries a Zacks Rank #3 (Hold). Better-ranked stocks include Forest Laboratories , Santarus Inc. and Jazz Pharmaceuticals (JAZZ - Analyst Report), all with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%